TLR4 and Hepatic fibrosis: Among those PPRs, the importance of TLR4 is well documented; indeed, TLR4 inhibition (TAK-242 or Serelaxin) has been shown to ameliorate injury and inflammation in rodent models of liver fibrosis, cirrhosis and ACLF (171–174).